HIV

ViiV Healthcare, a joint venture between GlaxoSmithKline plc (NYSE: GSK), Pfizer Inc (NYSE: PFE), and Shionogi, presented three-year results from the TANGO study at IDWeek 2021. Phase 3 TANGO study assessed the antiviral efficacy and safety of switching to Dovato...

Theratechnologies Inc (NASDAQ: THTX) has announced results from a study evaluating an intravenous (IV) push form of Trogarzo (ibalizumab-uiyk) for HIV-1 infection. The TMB-302 study was conducted by the Company's partner, TaiMed Biologics, to evaluate the current Trogarzo IV...

The United States Patent and Trademark Office has issued a notice of patent allowance to Indaptus Therapeutics Inc's (NASDAQ: INDP) platform technology. The patent provides broad protection for applying the Company's platform technology alone and in combination with...

Johnson & Johnson (NYSE: JNJ) and a consortium of global partners announced results from the primary analysis of a Phase 2b HIV vaccine trial, Imbokodo study. Data showed that the investigational HIV vaccine regimen did not provide sufficient protection against HIV infection in...

Merck & Co Inc (NYSE: MRK) has announced new data from Phase 2a trial evaluating islatravir for pre-exposure prophylaxis (PrEP) of HIV-1 infection in adults at low risk of contracting HIV-1.  After 24 weeks, once-monthly oral islatravir was generally well tolerated versus...

Gilead Sciences Inc (NASDAQ: GILD) announced long-term Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) data showing high efficacy and durable viral suppression in HIV patients. These data were presented at the 11th International AIDS Society...

Gilead Sciences Inc (NASDAQ: GILD) announced new Phase 3 data from the ongoing CAPELLA trial evaluating lenacapavir, its investigational, long-acting HIV-1 capsid inhibitor.  The data were presented at the 11th International AIDS Society (IAS) Conference on HIV Science. The...

In a first, a monthly injectable HIV drug made by a GlaxoSmithKline plc (NYSE: GSK)- and Pfizer Inc (NYSE: PFE)-owned company has received the approval of the United States Food and Drug Administration. What Happened: The injectable — Cabenuva — is designed to replace the current...

British pharmaceutical company GlaxoSmithKline PLC’s (NYSE: GSK) majority-owned subsidiary ViiV Healthcare received the marketing authorization approval for its HIV treatment in the European Union, the company announced on Monday. What Happened: ViiV announced that...

HIV patients may soon be eligible for a less burdensome dosing regimen based on the positive results announced Wednesday by GlaxoSmithKline plc (NYSE: GSK)-owned ViiV Healthcare for a late-stage study of its two-drug regimen for the disease.  What Happened ViiV Healthcare, in...

Gilead Sciences, Inc. (NASDAQ: GILD), which has recently faced a setback with its NASH pipeline and is grappling with an aging HIV franchise, is partnering with a privately held company to develop HIV therapies with the goal of improving medication adherence.  What Happened Lyndra...

The biotechnology sector remains highly competitive, and investors willing to take on a stock with a high-risk, high-growth profile may want to consider Gilead Sciences, Inc. (NASDAQ: GILD), according to Raymond James. The Analyst Raymond James' Steven Seedhouse initiated coverage of...

The new year has brought relief to Gilead Sciences, Inc. (NASDAQ: GILD)’s long-pressured stock, and one analyst projects a continuation in its U-shaped recovery. The Rating Jefferies analyst Michael Yee upgraded Gilead to Buy and raised the price target from $87 to $95. The Thesis...

Morgan Stanley reduced its price target on the shares of Mylan N.V. (NASDAQ: MYL) following downward revision to its estimates due to the IMS trends, generic price pressure and uncertain new launch timing. Meanwhile, in a separate note, Mylan announced its NDA for TLD, a combo of Lamivudhine...

The Congressional Budget Office has said that the Senate version of the Republicans’ Affordable Care Act replacement bill could result in 22 million fewer Americans with health insurance. That dramatic reduction in coverage could have major implications for drug makers offering expensive...